This model was used to identify immune gene-enriched tumors in arm A and arms B and C. Immune gene enrichment was linked to increased RFS in arms B and C ( HR , @ ; @ % CI , @ to @ ; P < @ ) , whereas arm B and C patients who did not exhibit immune gene enrichment did not benefit from trastuzumab ( HR , @ ; @ % CI , @ to @ ; P = @ ) .